Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A two stage randomized, open label, parallel group, phase III, multicenter, 7 month study to assess the efficacy and safety of Symbicort [budesonide/formoterol] pMDI [pressurised metered dose inhalers] adminstered either as fixed or as an adjustable regimen versus a fixed regimen of advair [salmeterol/fluticasone propionate] in subjects 12 yrs of age and older with asthma.

Trial Profile

A two stage randomized, open label, parallel group, phase III, multicenter, 7 month study to assess the efficacy and safety of Symbicort [budesonide/formoterol] pMDI [pressurised metered dose inhalers] adminstered either as fixed or as an adjustable regimen versus a fixed regimen of advair [salmeterol/fluticasone propionate] in subjects 12 yrs of age and older with asthma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2010

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca

Most Recent Events

  • 19 May 2009 Results reported at the 105th International Conference of the American Thoracic Society.
  • 17 Apr 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top